outperform price
chang recommend
upgrad outperform pt improv
core remov account overhang
sidelin better part last
year think current pullback base disclosur
upgrad outperform
pt equat price-to-earnings ev/ebitda
equat upsid current level pleas
join us webinar et morn
go medtech/tool outlook thesi
see link webinar slide
call make call account
audit resolv near term
oper impactw believ
transit acceler revenue stori
rang driven
aakhi differenti b/ give potenti
ep upsid given upgrad
share outperform top pick larg cap
risk risk account investig
spill impact oper item rais
question fundament
link et webinar click
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
larg cap suppli co differenti b/ u/g op
product
new molecul pharma
revenu mix end market
year perf vs xlv slight o/p
debat account investig overhang oppti
read stock chart steadili outperform pre-account issu fundament chang
patient enrol pd trial
guid
myxredlin approv fda
result fy guid st
debat org guidanc expec expect bullish commentari around pipelin oppti
dexm brevibloc pharma
trump administr
put place initi
improv kidney care
emphasi connect
patient care
domin posit
renal care
add-on payment theranova
could come
reimburs
largest barrier adopt
dialyz payment
would remov complet
increment renal
compound-annual-growth-rate upsid lrp
debat acceler storydriven aakhi
debat pushback inabl acceler toplineaakhi could push rev rang
impact mm
impact mm
debat increment invest aakhi weigh seprafilm partli offset
fy ep upsid seprafilm
invest aakhi
theranova off-set
slight ep hit cash flow
consensu sg sale
sg sale
consensu sale
 sale
upgrad outperform pt tsr
st model rev
consensu ep
tad
pt equat price-to-earnings
premium target price-to-earnings repres
yield basi pt equat yield
ev/ebitda basi pt equat
ebitda net leverag provid bn
conclus make call
account audit resolv near
term oper impactw
believ transit
acceler revenue stori
rang driven aakhi differenti
b/ give potenti ep upsid given
upgrad share outperform
valuat methodolog base mix discount cash flow analysi rel valuat multipl
increas competit price pressur fluid system fda qualiti issu tax reform uncertainti inabl
articl articl
time dissemin decemb
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
